Skip to main content
Premium Trial:

Request an Annual Quote

N-of-One to Provide Clinical Interpretation Services for New England VA Oncology Program

NEW YORK (GenomeWeb) – N-of-One has been selected by the US Department of Veterans Affairs New England Veteran's Integrated Service Network to provide clinical interpretation services for its Precision Oncology Program, the company said today.

The program aims to test US veterans recently diagnosed with non-small cell lung cancer using next-generation sequencing panels, provide them individualized treatments, and allow them the opportuniity to participate in research.

N-of-One will work closely with Personalis and Personal Genome Diagnostics (PGDx), both of whom were tapped previously to support the program. PGDx provides targeted genomic testing services using its CancerSelect targeted gene panel, which detects alterations in 88 well-characterized genes that are associated with currently available or investigational treatments. Personalis was selected to perform clinical cancer testing and research services based on its ACE Extended Cancer Panel Test, which provides comprehensive genomic profiling of solid tumors and helps identify targeted treatment options.

For its part, N-of-One will handle the interpretation of the genomic data collected from testing. The company will also provide scientific and clinical evidence that supports possible therapeutic strategies relevant to each specific patient case, it said.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.